Prescription Drug Reform Gains Momentum: What the New Senate Bill Means for Plan Sponsors

ProCare Rx Team • April 15, 2025

Prescription Drug Reform Gains Momentum: What the New Senate Bill Means for Plan Sponsors

The Senate Judiciary Committee has unanimously advanced the Prescription Pricing for the People Act of 2025. The voice vote signals rare bipartisan agreement on a complex issue: prescription drug pricing and the role of pharmacy benefit managers (PBMs) in driving those costs.

The legislation, if passed, would require the Federal Trade Commission (FTC) to further investigate the practices of intermediaries in the pharmaceutical supply chain—and recommend policies that promote transparency and fair competition. It’s a move that reflects growing concern about market consolidation, limited pricing visibility, and the potential impact on patients and payers alike.

It’s also a step toward giving plan sponsors the information they need to make better decisions. And that’s something we believe in deeply.


What’s in the Prescription Pricing for the People Act of 2025?

The bill, introduced by Senator Chuck Grassley (R-IA), directs the FTC to examine how PBMs influence drug pricing, reimbursement, and patient access. Specifically, it calls for a study of:

  • PBM pricing and spread practices
    Investigating whether PBMs are reimbursing pharmacies less than they charge plan sponsors.
  • Patient steering to owned pharmacies
    Determining whether PBMs direct patients toward affiliated pharmacies, limiting choice and impacting independents.
  • Use of competitive pharmacy data
    Exploring how PBMs may use claims data from unaffiliated pharmacies to gain a market edge.
  • Formulary design and cost structure
    Looking at whether PBMs design formularies in ways that favor higher-cost drugs when lower-cost options are available.

The FTC would be required to submit an interim report within 180 days of enactment and a final report within one year—both with recommendations for legislative or regulatory action.

Why It Matters

This legislation comes amid broader concerns over how opaque pricing and consolidation in the pharmacy supply chain affect employers, health plans, and patients. As Congress takes a closer look, plan sponsors are being asked to do the same—evaluating whether their PBM relationships are really delivering on value, access, and cost control.

The push for oversight is less about political positioning and more about rebalancing the system. Right now, too many decision-making levers are hidden from the people actually footing the bill.


Supporting Plan Sponsor Control

While transparency is essential, it’s only part of the equation. At ProCare Rx, we believe that plan sponsors deserve more than visibility—they deserve control.

That means:

  • Contracts with clear terms and no surprise fees
  • Access to real-time data for smarter, faster decisions
  • The ability to customize benefit design, rather than accept a one-size-fits-all model
  • A pharmacy benefit partner that answers to you, not to shareholders or owned pharmacies

This is one of our Seven Pillars for a reason: when employers have more control, they can manage their risk more effectively, protect their members more thoughtfully, and ensure that pharmacy benefits remain sustainable long-term.


Looking Ahead

As the Prescription Pricing for the People Act of 2025 continues to move forward, we see an opportunity to bring greater balance to the pharmacy benefit landscape—one where decisions are driven by value, not volume.

For plan sponsors and the patients they serve, that’s a win.

We’ll continue to follow this legislation closely and share updates as they become available.


About ProCare Rx
ProCare Rx is a privately held, independent pharmacy benefit manager (PBM) that has empowered healthcare and self-insured organizations since 1988. We provide fully integrated, in-house solutions—including claims adjudication, clinical program design, pharmacy network access, cost containment, and data analytics—all supported in the U.S. Our flexible, transparent model serves self-insured employers, third-party administrators (TPA), brokers, health plans, health systems, managed care organizations (MCO), unions, workers’ compensation programs, Medicare, Medicaid, hospices, and other PBMs. With a proprietary technology platform, commitment to ethical operations, and a focus on lowest net cost, ProCare Rx delivers long-term value, clinical performance, and trusted pharmacy benefit partnerships.

Media Contact:
Marc Cohen, VP, Marketing and Sales
marketing@ProCareRx.com

By ProCare Rx Team August 18, 2025
This appointment brings together multiple parts of the business under one umbrella to best serve our PBM clients and members, assuring that ClearSight transparency and Lowest Net Cost remains at the forefront of the innovative organization.
By ProCare Rx Team August 5, 2025
When Courts and Care Collide: What the Arkansas PBM Ruling Means for the Industry
By ProCare Rx Team July 8, 2025
Prescription Drug Pricing: Will Policy Fix What Patients Feel?
By ProCare Rx Team June 2, 2025
Is Your PBM Working for You…Or Against You? How to Ask the Right Questions and Spot Red Flags in Pharmacy Benefit Management
By ProCare Rx May 20, 2025
ProCare Rx Announces New Executive Appointment and Launch of Technology Division to Drive Innovation and Growth The newly created role is expected to solidify leadership of the core technology infrastructure to both enhance support for current clients as well as developing additional value-added offerings to the marketplace.
By ProCare Rx Team May 19, 2025
Understanding the “Most Favored Nation” Drug Pricing Rule
By ProCare Rx Team May 19, 2025
ProCare Rx's Innovative Approach to Pharmacy Benefit Management
By ProCare Rx May 6, 2025
ProCare Rx Appoints John Drakulich as President of their PBM Business
By ProCare Rx Team April 21, 2025
ProCare Rx’s ProCare PharmacyCare, LLC Earns URAC Accreditation in Specialty Pharmacy
By ProCare Rx Team April 2, 2025
The White House recently launched the Make America Healthy Again Commission to address some of the biggest challenges in U.S. healthcare—including chronic disease, medication reliance, and drug safety. While the full impact remains to be seen, this initiative signals potential shifts in how prescription drugs are evaluated, priced, and prescribed. For plan sponsors, employers, and pharmacy benefits managers (PBMs), the key question is: How can we ensure medication access, affordability, and safety while staying ahead of possible regulatory changes? Reevaluating Medication Reliance One of the Commission’s focus areas is over-reliance on medication and treatments. This could lead to a push for more careful prescribing practices, increased scrutiny of high-cost drugs, and expanded support for alternative treatment methods. PBMs can play a proactive role by ensuring plan designs promote clinically effective, cost-conscious prescribing, including: Encouraging use of generics and biosimilars when available Implementing clinical programs that support appropriate prescribing Providing medication management resources to help members navigate treatment options Increased Attention on Drug Safety & Pricing The Commission also highlights food and drug quality and safety , reinforcing the need for greater transparency in pharmaceutical manufacturing and pricing . This could mean: Tighter regulations on imported medications and supply chain oversight More scrutiny on rebate structures and how drug prices are set A renewed focus on affordability strategies for plan sponsors and consumers For PBMs and health plans, transparent pricing models and clear rebate structures will be key to staying compliant and ensuring members have access to safe, fairly priced medications. Eliminating Conflicts of Interest in Health Research Another priority for the Commission is ensuring federally funded health research is free from conflicts of interest . This could impact how drug effectiveness is studied, how formularies are built, and how treatment guidelines are developed. Employers and health plans should work with PBMs that prioritize: Data-driven formulary management based on independent clinical outcomes Objective drug evaluations to balance cost and effectiveness Transparent partnerships with health providers and pharmaceutical companies What’s Next? The Make America Healthy Again Commission is still in its early stages, but its focus on medication reliance, drug safety, and pharmaceutical pricing should not be ignored. Employers and plan sponsors should be prepared for potential policy changes that could impact pharmacy benefits. By working with PBMs that prioritize clinical integrity, cost control, and member education , organizations can stay ahead of the curve and continue to provide high- quality, affordable healthcare solutions. Would you like to review your pharmacy benefits strategy? Let’s talk. Click the button below to learn more about ProCare Rx's Offering and signup to hear from one of our sales team.